Genetic Testing Startup 23andme, which was filed for bankruptcy earlier this year, Announced On Monday that he has agreed to sell the genetic data of his 15 million users with his main business, drug developer Regenronon Pharmaceuticals. The acquisition, which followed a insolvency auction, is priced at $ 256 million and is expected to close in the third quarter of this year.
Regeneron told 23andme customers that it would follow the 23nd’s privacy policy, which allows customers to request to remove their personal information.
Connected: ‘Surprised and disappointed’: All independent board members of 23andme resign, except CEO
“We assure 23nd customers that we are committed to protecting 23andme datasets,” Arisran Genetics Center chief Aris Bars, Said in a press release,
Bars said that the Regoron Genetics Center has experience with genetic data, processing about three million people in research studies should process the genetic information because it was Established in 2013Bars said that Regenronon has shared the founder vision of the 23andme genetics and the power of data. ,
The acquisition of Regenron includes a personal genome service of 23andme, which conducts DNA testing for genetic forecast, lineage and symptoms based on a small saliva sample. Under the acquisition, 23andme will continue its daily operations as an individual genomics service, but as a subsidiary of Regenron, and will continue to offer genetic testing.
Anne Wojikki. Photo for Vanity Fair by Cindy Ord/VF24/Getty Image
Connected: ‘Hard but necessary’: 23andme is cutting 40% of your workforce
The only part of the 23andme business that does not acquire is its telehland division, Lemon healthWhich is planned by 23andme. Company employees in other divisions other than Lamad Health, numbering around 300 employeesWill maintain your job.
The deal is still to be approved by a judge who oversees bankruptcy in the US bankruptcy court for the eastern district of Missouri.
23andme filed for bankruptcy in late March after a few years. The company’s reputation was one after the other Data Brech in 2023 About seven million people, or about half of the company’s data were highlighted. 23andme Agreed to pay $ 30 million To prosecute Breach in September, but data secrecy remains a matter of concern.
23andme founder Anne Wozaki, 51, Resigned After the news of bankruptcy as CEO of 23andme, but continued to serve in the board of directors of the company. Wojcicki, who Co-establishment 23andme In 2006 and Owner of 49% The company said it had resigned from the role of CEO to be “the best position” to bid for the company’s total ownership.
Wojcicki submitted some rejected proposals to buy 23andme, One in July 2024 And Another in February To buy all the stocks of the company which he had already not in cash for $ 2.53 per share, for an equity price of $ 74.7 million.
In September, all 23andme directors Resigned from the board Due to strategic gap with Wojcicki. They have been since ReplacedThe company shut down 40% of its workforce or more than 200 people in November to cost cost.
23andme went public Was more valuable in 2021 About $ 6 billion At its peak that year.
Connected: Silicon Valley’s pioneer and former YouTube CEO Susan Wojikki die on 56 – here is how he changed the tech industry
Genetic Testing Startup 23andme, which was filed for bankruptcy earlier this year, Announced On Monday that he has agreed to sell the genetic data of his 15 million users with his main business, drug developer Regenronon Pharmaceuticals. The acquisition, which followed a insolvency auction, is priced at $ 256 million and is expected to close in the third quarter of this year.
Regeneron told 23andme customers that it would follow the 23nd’s privacy policy, which allows customers to request to remove their personal information.
Connected: ‘Surprised and disappointed’: All independent board members of 23andme resign, except CEO
The rest of this article is closed.
Join the entrepreneur, To reach today.
